CN110333360A - Application of the interleukin-22 6 as biomarker in diagnosis, prognosis or Treatment monitoring pyemia - Google Patents
Application of the interleukin-22 6 as biomarker in diagnosis, prognosis or Treatment monitoring pyemia Download PDFInfo
- Publication number
- CN110333360A CN110333360A CN201910669025.3A CN201910669025A CN110333360A CN 110333360 A CN110333360 A CN 110333360A CN 201910669025 A CN201910669025 A CN 201910669025A CN 110333360 A CN110333360 A CN 110333360A
- Authority
- CN
- China
- Prior art keywords
- pyemia
- prognosis
- interleukin
- diagnosis
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
- G01N33/541—Double or second antibody, i.e. precipitating antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to biomarker technical field, the specific application for providing interleukin-22 6 as biomarker in diagnosis, prognosis or Treatment monitoring pyemia.The present invention provides interleukin-22s 6 can be used as a pyemic diagnosis index；And interleukin-22 6 can be used as an index of assessment pyemia severity and prognosis, can carry out pyemic prognosis and/or Treatment monitoring according to the expression of interleukin-22 6.
Description
Technical field
The present invention relates to biomarker technical fields, are examining more particularly to a kind of interleukin-22 6 as biomarker
Application in disconnected, prognosis or Treatment monitoring pyemia.
Background technique
Pyemia (sepsis) is a kind of extensive syndrome of clinical manifestation, by critical care medicine association, the world (Society
Of Critical Care Medicine) and European severe Medical Association (European Society of Intensive
Care Medicine) it is newly defined as " multiple organ dysfunction of threat to life caused by host's anti-infectious immunity is lacked of proper care ".Entirely
There are about 31,500,000 every year to suffer from pyemia for ball, wherein there are about 5,300,000 people because of pyemia death.Although being achieved in terms of Intensive Care Therapy huge
Big progress, but due to the absolute increase of the quantity of sepsis patient, the pyemic death rate is still high.Therefore,
Control pyemia, which has become medical field, significant problem to be solved.
Pyemic pathogenesis is sufficiently complex, is mainly considered caused by the imbalance of body anti-infectious immunity at present.Pyemia
In early days, various immunocytes pass through related to damage point of pattern recognition receptors (PRR) identification pathogen-associated molecular pattern (PAMP)
Subpattern (DAMP), activates immune response immediately, discharges excessive proinflammatory mediators, is formed " cytokine storm ", promotes scorching
Disease reaction.Proinflammatory reaction is conducive to the removing of pathogen, but also increases the immunologic mjury of body, and multiple organ dysfunction is caused to hinder
Hinder.Lasting proinflammatory environment influences the functional status of immune effector cell, eventually leads to immune cell function obstacle and immune fiber crops
Numbness.Therefore, immunoregulation disorder plays a crucial role in pyemia generating process, and from pyemic different pathological physiological stage
It filters out characteristic biomarker and is then subject to specific aim intervention, be the important hand of sepsis subject and targeted therapy
Section.
There are many function of pyemia biomarker, are mainly used for sepsis diagnosis, prognosis evaluation and Treatment monitoring, mesh
Preceding using more biomarker mainly includes c reactive protein (CRP), Procalcitonin (PCT) etc..CRP is a kind of non-specific
Property acute phase protein, 4-6 hour after infectious or non-infectious triggering inflammatory reaction increase, and reaches within 36-50 hours height
Peak, the horizontal of it are lowered with the recession of inflammation；But its sensibility and specificity is in difference that whether there is or not bacterium infections and thin
It is restricted on bacterium gradient of infection.The raising of PCT level is usually infecting early stage, and faster than CRP, reaches within 24-36 hours high
There is higher specificity at peak to bacterium infection；But in non-pyemia or infection, such as surgical operation, multiple injury, burn, heart source
Property shock and non-bacterial systemic inflammatory response also have different degrees of raising.The sensibility of existing pyemia biomarker and
It is specific insufficient, therefore, finds and have both the biomarker of hypersensitivity and specificity and be applied to clinical diagnosis of sepsis, pre-
It is of great significance afterwards with Treatment monitoring.
Summary of the invention
In view of the foregoing deficiencies of prior art, the purpose of the present invention is to provide a kind of interleukin-22s 6 as biology mark
Application of the will object in diagnosis, prognosis or Treatment monitoring pyemia, for solve it is current in sepsis diagnosis, prognosis evaluation, control
Treat the biomarker of monitoring problem insufficient on sensibility and specificity.
In order to achieve the above objects and other related objects, the present invention provides a kind of interleukin-22 6 and is examining as biomarker
Application in disconnected, prognosis or Treatment monitoring pyemia, the interleukin-22 6 are used to prepare or screen septicopyemia as biomarker
Disease diagnostic reagent, the reagent is for diagnosis of sepsis and/or prognosis and/or Treatment monitoring.
Optionally, the reagent is used to measure the expression quantity of IL-26 in humoral sample.
Optionally, the reagent detects the expression quantity of IL-26 by ELISA double-antibody method.
Optionally, the expression quantity of IL-26 and pyemic severity are positively correlated in the humoral sample.
Optionally, the humoral sample is selected from serum.
Optionally, the reagent for diagnose or monitor pyemic presence and/or process and/or severity and/or
Prognosis.
As described above, interleukin-22 6 of the invention is being prepared or is being screened in sepsis diagnosis reagent as biomarker
Using, have the advantages that on the one hand, can be used as a pyemic diagnosis the present invention provides interleukin-22 6 and refer to
Mark；On the other hand, the present invention provides the index that interleukin-22 6 can be used as assessment pyemia severity and prognosis, can root
Pyemic prognosis and/or Treatment monitoring are carried out according to the expression of interleukin-22 6.
Detailed description of the invention
Fig. 1 a is shown as in the embodiment of the present invention 1 IL-26 expression quantity inspection in sepsis patient and the blood of normal healthy controls person
Survey result figure.
Fig. 1 b is shown as in the embodiment of the present invention 1 with the blood of the sepsis patient of shock and the sepsis patient of non-shock
IL-26 expression quantity testing result figure in liquid.
Fig. 1 c is shown as in the embodiment of the present invention 1 IL-26 expression quantity detection in pyemia died and the blood of survivor
Result figure.
Fig. 1 d is shown as in the embodiment of the present invention 1 expression quantity of IL-26 and SOFA scoring correlation in sepsis patient body
Analyze result figure.
Fig. 2 is shown as ROC curve comparative analysis IL-26 and the diagnosis of PCT, CRP in pyemia in the embodiment of the present invention 2
Effect diagram.
Fig. 3 is shown as the survival rate statistics of IL-26 albumen processing group mouse and control group mice in the embodiment of the present invention 3
Figure.
Fig. 4 is shown as the liver and kidney dysfunction testing result figure of mouse in the embodiment of the present invention 4.
Fig. 5 is shown as the organ pathological section and pathology damage scoring figure of mouse in the embodiment of the present invention 5.
Specific embodiment
Illustrate embodiments of the present invention below by way of specific specific example, those skilled in the art can be by this specification
Other advantages and efficacy of the present invention can be easily understood for disclosed content.The present invention can also pass through in addition different specific realities
The mode of applying is embodied or practiced, the various details in this specification can also based on different viewpoints and application, without departing from
Various modifications or alterations are carried out under spirit of the invention.
Interleukin-26 (IL-26, interleukin-22 6), original is named as AK155, is to be ground in 2000 by Knappe et al.
When studying carefully the conversion T cell of herpes simplex virus (HSV), a new cDNA (AK155) being screened from gene library.Due to it
Amino acid sequence and receptor structure and IL-10 family member have certain similitude, become IL-10 cytokine family afterwards
Member, and be named as IL-26.IL-26 is mainly generated by epithelial cell and immunocyte (Th17 cell, macrophage),
The heterodimer that its receptor is made of IL-20R1 and IL-10R2.Currently, the research about IL-26 is concentrated mainly on chronic inflammation
In disease property disease, inside rheumatoid arthritis, Behcet's disease, Crohn disease and psoriasis.Pertinent literature is reported in class wind
In wet arthritis (RA) patients serum and joint fluid, IL-26 expression is significantly improved, and IL-26 has and promotes macrophage
The effect of cell upregulation expression of proinflammatory cytokines.Equally, in Behcet's disease (BD) patients serum, IL-26 expression
It is significantly improved, and the expression of Th-17 relevant cell factor such as IL-17 can be promoted.However, IL-26 grinding in terms of pyemia
Studying carefully is still blank out.
The present invention probes into discovery by a series of, and IL-26 takes part in pyemic occurrence and development process, and can make
For a kind of good diagnosis of sepsis, the biomarker of prognosis and Treatment monitoring.
Pass through ELISA method detection 6 table of serum IL-2 of 52 sepsis patients and 30 health examination collators first
It up to level, finds compared with normal healthy controls person, IL-26 content is significantly raised in sepsis patient body, with the pyemia of shock
Patient is apparently higher than the sepsis patient of non-shock, and pyemia died IL-26 content is higher than survivor；Meanwhile Wo Mentong
Cross correlation analysis discovery, IL-26 level and sequential organ failure score (SOFA) be positively correlated, and pass through ROC curve analysis
The indexs such as PCT, CRP, discovery IL-26 area under the curve are apparently higher than the indexs such as PCT, CRP.Therefore, IL-26 can be used as purulence
The diagnosis index of toxication, and pyemic severity can be reacted.
Further, the present invention is built by Cecal Ligation centesis (Cecal Ligation and Puncture, CLP)
Vertical mouse sepsis model, and IL-26 recombinant protein is injected to albumen processing group mouse peritoneal, it is injected intraperitoneally to control group mice
The survival rate of the PBS of equal volume, discovery albumen processing group mouse are significantly lower than the survival rate of control group mice；And tissue HE dye
Color result also show the inflammatory cells of the organs such as liver, lung, the kidney of albumen processing group mouse compared with infiltrated compared with control group mice, it is congested more
Obviously, histopathology scoring is higher；At the same time, the biochemical indicators such as liver kidney function are also significantly raised.These results illustrate IL-26
The damage for having aggravated sepsis patient histoorgan can be used as the index of assessment pyemia severity.
To the experiment that following embodiment is related to, it is described as follows:
Study population: the pyemia of collection in August, 2017 in June, 2018 Hospital, No. 1, Affiliated to chongqing Medical Univ.'s diagnosis and treatment
Blood samples of patients is test group, and same period physical examination of healthy population is healthy control group, and test group men and women is respectively 35 (67.3%), 17
(32.7%) example, control group men and women are respectively 21 (70.0%) examples, 9 (30.0%) examples.Sample is placed in 4 DEG C of 1 400 × g centrifugations
7min, freezes later at -80 DEG C, detects the IL-26 protein expression level in serum by ELISA.Patient meets international purulence
To the diagnostic criteria Sepsis 3.0 of the disease in toxication meeting, exclude to be lower than 7g/ with malignant tumour, HIV infection, hemoglobin
ML or there are active hemorrhage, need two units more than red blood cell situations such as, subject it is all research cured through Chongqing
University, section the first affiliated hospital science and Ethics Committee ratify.
Experimental animal: wild type C57BL/6 mouse (Wild type, WT) male mice, weight 18-22g, about 6-8 weeks
Age, purchase are raised from Beijing HFK Bio-Technology Co., Ltd. in Medical University Of Chongqing Experimental Animal Center SPF
The grade laboratory (Specific Pathogen Free), mouse used in the experiment is SPF grades of experimental animals.Zoopery is tight
The laboratory animal that lattice follow the promulgation of the Department of Science and Technology, the People's Republic of China (PRC) takes care of and guide for use, meets Medical University Of Chongqing's experiment
Animal welfare regulation good at managing.Experimental animal credit number: SCKK (Chongqing) 2012-0001.
Specific implementation process is as follows:
Embodiment 1
The detection of IL-26 content and SOFA scoring correlation analysis in sepsis patient blood
Collecting 52 clinical sepsis patients (includes that 23 pyemias with shock are suffered from 52 clinical sepsis patients
The sepsis patient of person and 29 non-shocks, wherein 18 death, 34 survivals) and 30 health examination collators on the day of blood
Clear sample (referring to table 1), carries out check experiment, passes through ELISA kit (being purchased from LifeSpan company, article No. LS-F4914) inspection
IL-26 expression quantity is surveyed, operating procedure is executed in strict accordance with specification appended by kit, then will test result SPSS 19.0
Software does statistical analysis, is mapped with 5.0 software of GraphPad Prism.
1 sepsis patient of table and physical examination of healthy population data statistics result
Fig. 1 a is shown as IL-26 expression quantity testing result figure in sepsis patient and the blood of normal healthy controls person, and Fig. 1 b is aobvious
It is shown as IL-26 expression quantity testing result figure in the blood of the sepsis patient of the sepsis patient and non-shock with shock, is schemed
1c is shown as IL-26 expression quantity testing result figure in pyemia died and the blood of survivor, and Fig. 1 d is shown as pyemia trouble
The expression quantity of IL-26 and SOFA scoring correlation analysis result figure in person's body.As the result is shown: compared with normal healthy controls person, IL-26
Level is significantly raised in sepsis patient body, and difference has statistical significance (P < 0.001)；Suffer from the pyemia of shock
The intracorporal IL-26 content of sepsis patient that the intracorporal IL-26 content of person is apparently higher than non-shock, difference have statistical significance
(P < 0.001)；In sepsis patient, the intracorporal IL-26 content of died is significantly higher than the intracorporal IL-26 of survivor (P <
0.05), and in sepsis patient body the expression quantity of IL-26 is positively correlated with SOFA scoring.Therefore, IL-26 can be used as clinic
The index of sepsis diagnosis, and pyemic severity can be prompted.
Embodiment 2
ROC curve analysis compares serum IL-2 6, PCT and CRP to the predictive value of pyemia prognosis
The IL-26 for collecting PCT, CRP of the sepsis patient survival and Died Patients in embodiment 1 and detecting is horizontal
Value, uses SPSS19.0 Software on Drawing ROC curve.
Fig. 2 is shown as ROC curve comparative analysis IL-26 and the diagnosis effect schematic diagram of PCT, CRP in pyemia.As a result
Display: the area under the curve (Area under the Curve, AUC) of IL-26 is 0.690, and below the curve of PCT and CRP
Product is respectively that the area under the curve of 0.552,0.370, IL-26 is significantly greater than PCT and CRP, this shows compared with than PCT, CRP,
IL-26 is bigger to the predictive value of pyemia prognosis.
Embodiment 3
The experiment of mouse survival rate
Mouse sepsis model is initially set up, the foundation of pyemia animal model uses Cecal Ligation centesis (cecal
Ligation and puncture, CLP), the specific operation method is as follows: adult C57 mouse is selected, with 100 microlitre 1.5%
Yellow Jackets intraperitoneal injection of anesthesia mouse, is fixed on operation panel, and abdomen pet electric hair cutter shaving sterilizes skin, just in abdomen
In do the notch of 1cm long, cecal ligation is punctured with No. 26 syringe needles, is finally sewed up a wound, and sterilizes skin.(specific experiment
Method reference: Daniel Rittirsch, Peter A Ward, et al.Immunodesign of experimental
sepsis by cecal ligation and puncture.Nat Protoc.2009；4 (1): 31-36).The modeling method
It is the classical modeling method of pyemia animal model, and the model is to study pyemic standard animal model at present.)
30 adult C57 mouse are selected, establish mouse sepsis model according to above-mentioned pyemia method for building animal model,
Then three groups are divided into, two groups are albumen processing group, and one group is control group；Respectively to the mouse abdomen of a wherein histone processing group
Chamber volume injected be 100ul, dosage be 500ng 6 albumen of recombinant il-2 (R&D systems, 1870-IL-010), another group
The mouse peritoneal volume injected of albumen processing group be 100ul, dosage be 1.0ug 6 albumen of recombinant il-2 (R&D systems,
1870-IL-010), to the sterile PBS of the mouse peritoneal injection equal volume of control group；The existence feelings of mouse twice are observed daily
Condition, and weight is recorded, continuous two weeks or so, until mouse is no longer dead.
Fig. 3 is shown as the survival rate statistics figure of IL-26 albumen processing group mouse and control group mice.As the result is shown: 500ng
The mouse survival rate of IL-26 processing group is 40%, and the mouse survival rate of 1ug IL-26 albumen processing group is 20%, obviously
Lower than the control group that survival rate is 80%, illustrate that IL-26 increases the death rate of pyemia mouse, damage is played in Mice Body and is made
With, that is, show IL-26 can be used as assessment pyemia severity index.
Embodiment 4
Mouse Liver kidney function etc. can biochemical indicator detection
10 adult C57 mouse are selected, establish mouse according to pyemia method for building animal model described in embodiment 3
Sepsis model, and it is divided into albumen processing group and control group, and according to method same in embodiment 3 respectively to two groups of mouse
Inject the IL-26 albumen and PBS of equal volume.
After 48 hours, mouse heart blood is taken, takes supernatant after centrifugation, detection liver kidney function index such as alanine aminotransferase (ALT),
Aspartic transaminase (AST), lactic dehydrogenase (LDH) and creatinine (Creatinine).
Fig. 4 is shown as the liver and kidney dysfunction testing result figure of mouse.As the result is shown: compared with the control group, IL-26 albumen
Liver kidney function index ALT, AST, LDH, Creatinin of processing group mouse are significantly raised, and the specific statistical significance of difference (P <
0.05), illustrate for sepsis patient, IL-26 can aggravate the damage of histoorgan, and therefore, IL-26 can be used as can be with
Index as assessment pyemia severity.
Embodiment 5
The detection of mouse tissue pathology
10 adult C57 mouse are selected, establish mouse according to pyemia method for building animal model described in embodiment 3
Sepsis model, and it is divided into albumen processing group and control group, and according to method same in embodiment 3 respectively to two groups of mouse
Inject the IL-26 albumen and PBS of equal volume.
After 48 hours, the histoorgans such as Mouse Liver, spleen, lung, kidney are taken, 24~48 hours are fixed in 4% paraformaldehyde, point
Be not dehydrated, waxdip, embedding, slice, after HE is dyed under microscope microscopy.
Fig. 5 is shown as the organ pathological section and pathology damage scoring figure of mouse.As the result is shown: compared with the control group, IL-
Mouse tissue organ inflammation cellular infiltration, the congestion and edema of 26 albumen processing groups become apparent from, and pathological score is anticipated with statistics
Adopted (P < 0.05), illustrates that IL-26 has aggravated the damage of sepsis patient histoorgan, can be used as the assessment serious journey of pyemia
The index of degree.
In conclusion present invention discover that IL-26 is apparently higher than health examination in the intracorporal expression quantity of clinical sepsis patient
Person, and be positively correlated with the SOFA of sepsis patient scoring, and find that IL-26 can be used as prediction septicopyemia by ROC curve analysis
One new biological markers of disease prognosis；And found further across interior animal experiment, IL-26 albumen can aggravate septicopyemia
The damage of disease mouse tissue organ, increases the death rate of mouse, detrimental effect is played in Mice Body.Therefore, the present invention provides
The index of diagnosis, prognosis and Treatment monitoring that IL-26 is infected as pyemia, and pyemia severity can be assessed.
The above-described embodiments merely illustrate the principles and effects of the present invention, and is not intended to limit the present invention.It is any ripe
The personage for knowing this technology all without departing from the spirit and scope of the present invention, carries out modifications and changes to above-described embodiment.Cause
This, institute is complete without departing from the spirit and technical ideas disclosed in the present invention by those of ordinary skill in the art such as
At all equivalent modifications or change, should be covered by the claims of the present invention.
SEQUENCE LISTING
<110>Medical University Of Chongqing
<120>application of the interleukin-22 6 as biomarker in diagnosis, prognosis or Treatment monitoring pyemia
<130> 2019
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 171
<212> PRT
<213> Artificial
<220>
<223>interleukin-22 6
<400> 1
Met Leu Val Asn Phe Ile Leu Arg Cys Gly Leu Leu Leu Val Thr Leu
1 5 10 15
Ser Leu Ala Ile Ala Lys His Lys Gln Ser Ser Phe Thr Lys Ser Cys
20 25 30
Tyr Pro Arg Gly Thr Leu Ser Gln Ala Val Asp Ala Leu Tyr Ile Lys
35 40 45
Ala Ala Trp Leu Lys Ala Thr Ile Pro Glu Asp Arg Ile Lys Asn Ile
50 55 60
Arg Leu Leu Lys Lys Lys Thr Lys Lys Gln Phe Met Lys Asn Cys Gln
65 70 75 80
Phe Gln Glu Gln Leu Leu Ser Phe Phe Met Glu Asp Val Phe Gly Gln
85 90 95
Leu Gln Leu Gln Gly Cys Lys Lys Ile Arg Phe Val Glu Asp Phe His
100 105 110
Ser Leu Arg Gln Lys Leu Ser His Cys Ile Ser Cys Ala Ser Ser Ala
115 120 125
Arg Glu Met Lys Ser Ile Thr Arg Met Lys Arg Ile Phe Tyr Arg Ile
130 135 140
Gly Asn Lys Gly Ile Tyr Lys Ala Ile Ser Glu Leu Asp Ile Leu Leu
145 150 155 160
Ser Trp Ile Lys Lys Leu Leu Glu Ser Ser Gln
165 170
Claims (6)
1. application of the interleukin-22 6 as biomarker in diagnosis, prognosis or Treatment monitoring pyemia, it is characterised in that: institute
Interleukin-22 6 is stated as biomarker and is used to prepare or screens sepsis diagnosis reagent, the reagent is used for diagnosis of sepsis
And/or prognosis and/or Treatment monitoring.
2. application according to claim 1, it is characterised in that: the reagent is used to measure the table of IL-26 in humoral sample
Up to amount.
3. application according to claim 2, it is characterised in that: the reagent detects IL-26 by ELISA double-antibody method
Expression quantity.
4. application according to claim 2, it is characterised in that: the expression quantity and pyemia of IL-26 in the humoral sample
Severity be positively correlated.
5. application according to claim 2, it is characterised in that: the humoral sample is selected from serum.
6. application according to claim 1, it is characterised in that: the reagent is for diagnosing or monitoring pyemic presence
And/or process and/or severity and/or prognosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910669025.3A CN110333360B (en) | 2019-08-15 | 2019-08-15 | Application of interleukin 26 as biomarker in diagnosis, prognosis or treatment monitoring of sepsis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910669025.3A CN110333360B (en) | 2019-08-15 | 2019-08-15 | Application of interleukin 26 as biomarker in diagnosis, prognosis or treatment monitoring of sepsis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110333360A true CN110333360A (en) | 2019-10-15 |
| CN110333360B CN110333360B (en) | 2020-05-15 |
Family
ID=68147319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910669025.3A Expired - Fee Related CN110333360B (en) | 2019-08-15 | 2019-08-15 | Application of interleukin 26 as biomarker in diagnosis, prognosis or treatment monitoring of sepsis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110333360B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113215249A (en) * | 2021-06-29 | 2021-08-06 | 中国人民解放军军事科学院军事医学研究院 | IL-26 for the identification and diagnosis of anxious depression |
| CN114113631A (en) * | 2021-11-26 | 2022-03-01 | 北京医院 | Sepsis detection kit |
| CN114184693A (en) * | 2021-10-14 | 2022-03-15 | 重庆医科大学 | Application of 4-hydroxyphenylacetic acid as marker in preparation of diagnostic kit for sepsis encephalopathy |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107389925A (en) * | 2017-07-28 | 2017-11-24 | 上海交通大学医学院附属上海儿童医学中心 | The bigeminy colloidal gold immunochromatographykit kit of IL 6 and IL 10 for pyemia quick diagnosis |
| CN108333373A (en) * | 2018-03-28 | 2018-07-27 | 徐昉 | The application of serum levels of inflammatory cytokines |
-
2019
- 2019-08-15 CN CN201910669025.3A patent/CN110333360B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107389925A (en) * | 2017-07-28 | 2017-11-24 | 上海交通大学医学院附属上海儿童医学中心 | The bigeminy colloidal gold immunochromatographykit kit of IL 6 and IL 10 for pyemia quick diagnosis |
| CN108333373A (en) * | 2018-03-28 | 2018-07-27 | 徐昉 | The application of serum levels of inflammatory cytokines |
Non-Patent Citations (1)
| Title |
|---|
| VINCENT LAROCHETTE1等: "IL-26, a Cytokine With Roles in Extracellular DNA-Induced Inflammation and Microbial Defense", 《FRONTIERS IN IMMUNOLOGY》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113215249A (en) * | 2021-06-29 | 2021-08-06 | 中国人民解放军军事科学院军事医学研究院 | IL-26 for the identification and diagnosis of anxious depression |
| CN114184693A (en) * | 2021-10-14 | 2022-03-15 | 重庆医科大学 | Application of 4-hydroxyphenylacetic acid as marker in preparation of diagnostic kit for sepsis encephalopathy |
| CN114184693B (en) * | 2021-10-14 | 2023-10-13 | 重庆医科大学 | Application of 4-hydroxyphenylacetic acid as marker in preparation of diagnosis kit for sepsis encephalopathy |
| CN114113631A (en) * | 2021-11-26 | 2022-03-01 | 北京医院 | Sepsis detection kit |
| CN114113631B (en) * | 2021-11-26 | 2024-02-20 | 北京医院 | Sepsis detection kit |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110333360B (en) | 2020-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110333360A (en) | Application of the interleukin-22 6 as biomarker in diagnosis, prognosis or Treatment monitoring pyemia | |
| CN105506115B (en) | A kind of DNA library and its application of checkout and diagnosis genetic cardiomyopathies Disease-causing gene | |
| CN107545135B (en) | The construction method of hepatitis B liver diseases T lymphocyte immune state application assessment models | |
| WO2022012292A1 (en) | Peripheral blood tcr marker for pancreatic cancer, and detection kit and use thereof | |
| CN111693702A (en) | Peripheral blood TCR marker of melanoma and detection kit and application thereof | |
| CN112321700A (en) | Novel coronavirus-infected peripheral blood TCR marker and detection kit and application thereof | |
| US9863952B2 (en) | Method for the diagnosis of higher- and lower-grade astrocytoma using biomarkers and diagnostic kit thereof | |
| RU2583939C1 (en) | Method for laboratory diagnosis of stages of hepatic fibrosis in chronic viral hepatitis c | |
| WO2022194033A1 (en) | Peripheral blood tcr marker for diffuse large b-cell lymphoma, and detection kit and use therefor | |
| Reis et al. | Biomarkers of pelvic endometriosis | |
| CN117214442A (en) | Use of mesencephalon astrocyte-derived neurotrophic factor as biomarker and therapeutic target in sepsis | |
| CN108535492B (en) | Purposes of the AIM as biomarker in diagnosis, prognosis or monitoring pyemia | |
| CN107557490B (en) | Use of CXCL13 as biomarker in diagnostic reagents | |
| CN104330564B (en) | Test kit for NPC early diagnosis | |
| CN112180093B (en) | Critical disease mortality diagnostic biomarker tenascin-c and application thereof | |
| CN111721940A (en) | Application of MICB protein expression quantity detection reagent in preparation of kit for identifying depressive disorder and bipolar disorder | |
| CN107858415A (en) | Biomarker combinations and its application for uterus adenomyosis detection | |
| CN105785035A (en) | Kit for diagnosing hepatocellular carcinoma | |
| CN109884320A (en) | Application of the oncostatinM as biomarker in preparation sepsis diagnosis reagent | |
| CN107345967A (en) | Purposes of the GP73 albumen as serum markers in cancer is diagnosed | |
| Widuri et al. | Eosinophil Level with Severity of Sepsis Based on Sequential Organ Failure Assessment Score. | |
| CN110004220A (en) | A kind of psoriasis blood serum designated object and its application | |
| CN108956997A (en) | CD151 expressing quantity ELISA detection method and kit | |
| Al-Taie et al. | Evaluation of IL-4 and IL-12 concentration in patient of Hydatid Cyst | |
| CN103314299A (en) | Composition including thioredoxin 1 as active ingredient, for diagnosis of ovarian cancer or pneumonia, and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200515 Termination date: 20200815 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |